SPA
RPRX icon

Sherbrooke Park Advisers’s Royalty Pharma RPRX Stock Holding History

Sherbrooke Park Advisers’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6,050
Closed -$213K – 479
2025
Q3 		$213K Buy
+6,050
New +$219K 0.1% 368
2025
Q1 		– Sell
-34,891
Closed -$890K – 886
2024
Q4 		$890K Buy
34,891
+380
+1% +$10.1K 0.28% 72
2024
Q3 		$976K Buy
34,511
+17,543
+103% +$486K 0.22% 85
2024
Q2 		$447K Buy
+16,968
New +$470K 0.08% 466

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sherbrooke Park Advisers's RPRX Position: Q4 2025 in Review

Sherbrooke Park Advisers sold out of Royalty Pharma (RPRX) in Q4 2025, closing a stake of 6,050 shares — an estimated $213K sold.

Sherbrooke Park Advisers first reported a position in RPRX in Q2 2024 and held it in 4 quarters. The position peaked at $976K in Q3 2024. 539 funds tracked by Wall St. Rank hold RPRX as of Q4 2025.

  • Sherbrooke Park Advisers reported no remaining Royalty Pharma position as of Q4 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 6,050 Royalty Pharma shares in Q4 2025, an estimated $213K.
  • Sherbrooke Park Advisers first reported a position in Royalty Pharma in Q2 2024 and held it in 4 quarters.
  • Sherbrooke Park Advisers's Royalty Pharma position peaked at $976K in Q3 2024.
  • 539 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.